Short Interest in Lumos Pharma, Inc. (NASDAQ:LUMO) Increases By 22.7%

Lumos Pharma, Inc. (NASDAQ:LUMO) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 361,500 shares, a growth of 22.7% from the June 30th total of 294,700 shares. Based on an average daily volume of 34,000 shares, the days-to-cover ratio is presently 10.6 days. Currently, 7.0% of the company’s shares are short sold.

Lumos Pharma Trading Up 1.2 %

Shares of LUMO stock traded up $0.02 on Tuesday, reaching $1.78. The company had a trading volume of 50,415 shares, compared to its average volume of 27,527. The stock has a market cap of $14.47 million, a PE ratio of -0.38 and a beta of 0.72. The company has a 50-day moving average of $2.11 and a 200-day moving average of $2.60. Lumos Pharma has a 12 month low of $1.37 and a 12 month high of $4.55.

Lumos Pharma (NASDAQ:LUMO) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.08). The company had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.51 million. Lumos Pharma had a negative net margin of 2,434.69% and a negative return on equity of 119.87%. During the same period last year, the company earned ($0.89) earnings per share. Sell-side analysts anticipate that Lumos Pharma will post -3.15 earnings per share for the current year.

About Lumos Pharma

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.